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AbstrAct:
Mutations in DNMT3A encoding DNA methyltransferase 3A were recently described 
in patients with acute myeloid leukemia. To assess their prognostic significance, 
we determined the mutational status of DNMT3A exon 23 in 288 patients with AML 
excluding acute promyelocytic leukemia, aged from 18 to 65 years and treated in 
Toulouse University Hospital. A mutation was detected in 39 patients (13.5%). 
All  DNMT3A  exon 23+ patients had intermediate-risk cytogenetics. Mutations 
significantly  correlated  with  a  higher  WBC  count  (p<0.001),  NPM1  (p<0.001) 
and FLT3-ITD mutations (p=0.027). DNMT3A mutations were conserved through 
xenotransplantation in immunodeficient mice. No difference in outcome between 
DNMT3A exon 23+ and DNMT3A exon 23- patients was found even if the results 
were stratified by NPM1 or FLT3-ITD status. However, DNMT3A exon 23+ patients 
had better median DFS (not reached vs 11.6 months, p=0.009) and OS (not reached 
vs 14.3 months, p=0.005) as compared to DNMT3A exon 23- patients when treated 
with idarubicin, whereas patients treated with daunorubicin had similar outcome 
regardless the DNMT3A status. This study shows that DNMT3A mutations have no 
impact on outcome but could be a predictive factor for response to idarubicin and 
thus, could have a direct influence in the way AML patients should be managed.
IntroductIon
Acute myeloid leukemia (AML), most 
widespread acute leukemia in adults, is characterized 
by clonal proliferation of oncogenic event-transformed 
hematopoietic stem cells or progenitors. Despite a high 
rate of complete remission after treatment with intensive 
chemotherapy combining cytarabine and anthracyclines 
in schemas that have little changed during the past 30 
years, relapse rates are very high, resulting in a poor 
outcome in most cases with 5-year overall survival 
of 40% in younger adults and only 10-15% in elderly 
patients [1]. Nevertheless, therapeutic results drastically Oncotarget 2011; 2:  850 - 861 851 www.impactjournals.com/oncotarget
vary regarding the main prognostic factors including 
age, performance status, cytogenetic and molecular 
abnormalities. Indeed, the knowledge of molecular basis 
of AML has considerably increased in the past few years 
mostly through the identification of recurrent mutational 
events occurring in a substantial number of patients [2].
The leukemic clone emerges from normal 
hematopoietic stem cells or more mature myeloid 
progenitors after acquisition of gene mutations affecting 
cell differentiation and self-renewal (such as the fusion 
genes PML-RARA, AML1-ETO, CBFb-MYH11 or point 
mutations targeting the functions of CEBPA, RUNX1, MLL 
or NPM1), cell signaling (FLT3, RAS or KIT), epigenetic 
machinery (TET2) and cell metabolism (IDH1 or IDH2) 
[3-4]. These mutations particularly occur in AML without 
chromosomal abnormalities detected (normal karyotypes) 
and represent a major issue in the clinical management 
of patients since they could provide targets for both 
therapy (i.e., tyrosine kinase inhibitors in FLT3-ITD 
positive AML) and molecular monitoring of residual 
disease. However, the major impact of these mutations 
resides  in  the  stratification  of  consolidation  therapy 
once complete response is achieved following induction 
chemotherapy. It is now generally accepted that patients 
with normal karyotype and favorable genotype (i.e., 
NPM1 or CEBPA mutations without FLT3-ITD mutations) 
are no longer referred to allogeneic hematopoietic stem-
cell  transplantation  (HSCT)  in  first  complete  response 
since their outcome with chemotherapy alone is similar 
to those receiving HSCT [5]. In addition, patients with 
an unfavorable genotype are more readily directed to 
allograft from unrelated donors or cord blood units since 
their prognosis with chemotherapy alone is dismal. Thus, 
FLT3-ITD, CEBPA, NPM1 mutations are now part of the 
initial work up of all AML patients with intermediate 
cytogenetic risk who undergo intensive treatments [6]. 
However, newly discovered mutations such as isocitrate 
dehydrogenase 1 and 2 (IDH1/2) mutations have been 
already  proposed  to  refine  this  molecular  stratification 
although their prognostic impact remains to be definitely 
established [7-8]. 
Even more recently, by sequencing the genome 
of leukemic cells from a patient with AML, Ley et al 
have detected somatic mutations in the gene of a DNA 
methyltransferase (MTase), DNMT3A [9]. DNMT3A is a 
member of the DNA MTases family including DNMT1, 
DNMT2, DNMT3A and DNMT3B that are involved in the 
methylation of CpG islands [10]. The hypermethylation 
of CpG islands that contributes to the downregulation 
of gene expression, and notably of tumor suppressor 
genes, is also a hallmark of AML [11]. In a series of 281 
de novo AML, DNMT3A mutations were found in 22% 
of cases, clustering in intermediate-risk cytogenetic 
group and associated with a poor outcome. Most of the 
DNMT3A mutations (60%) found in AML samples were 
missense mutations localized on the R882 amino acid of 
the MTase domain. It is noteworthy that R882 mutations 
were significantly associated with a high white blood cell 
count as compared with other DNMT3A mutations. The 
aim of our study was to confirm the prognostic impact of 
R882 DNMT3A mutations in a series of 288 AML patients 
treated in our institution and to evaluate its screening 
usefulness in the medical diagnosis process, in a similar 
way to KIT exon 17 screening. 
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Figure 1: Flow chart of AML patients treated by intensive chemotherapy between 2000 and 2009. From 2000 to 2009, 
457 consecutive patients with de novo AML were treated by intensive chemotherapy. Patients with acute promyelocytic leukemia or with 
secondary AML were excluded from this study.Oncotarget 2011; 2:  850 - 861 852 www.impactjournals.com/oncotarget
PAtIents And Methods
Patients and treatments
From 2000 to 2009, 457 consecutive patients (18-
65 years) with untreated de novo AML (excluding acute 
promyelocytic leukemia and secondary AML) were 
admitted for intensive chemotherapy induction at the 
Hematology department of Toulouse University hospital. 
In this cohort of patients, 288 samples were available for 
genetic screening. Since DNMT3A mutations were only 
observed in the intermediate-cytogenetic risk group, 
the therapeutic outcome was assessed in this population 
(n=194).  Figure  1  shows  the  flow  chart  of  all  AML 
patients in this period of time. From this cohort of 194 
intermediate-risk  patients,  those  ≤  60  years  (n=156) 
received either daunorubicin (dnr) (60 mg/m2, d1-3) 
(n=112) or idarubicin (ida) (8 mg/m2, d1-5) (n=44) with 
cytarabine (AraC) (200 mg/m2, d1-7). A second course 
(ida, 8mg/m2 or dnr, 35mg/m2 d17-18 and AraC, 1g/
m2/12h d17-20) was delivered if more than 5% marrow 
blasts persisted on d15 [12]. Patients were treated according 
to institutional guidelines using daunorubicin as main 
anthracycline while some of them received idarubicin 
as part of a randomized clinical trial [12]. Patients in 
complete response (CR) with HLA-identical sibling were 
planned to receive allo-HSCT: (i) after a myeloablative 
conditioning regimen consisting of oral busulfan (16 
mg/kg over 4 days) and cyclophosphamide (120 mg/kg 
over 2 days) for patients less than 51 years; (ii) after one 
course of intensive consolidation described below and 
reduced intensity conditioning, (oral busulfan, 8 mg/kg 
over 2 days, fludarabine, 120 mg/m2 over 4 days, rabbit 
anti-thymocyte globulins 2,5 mg/kg on d-4 and d-3) for 
patients between 51 and 60 years. Patients with no HLA-
identical sibling received a consolidation regimen (ida, 
12 mg/m2 or dnr, 60 mg/m2 d1-2 and AraC 3 g/m2/12h 
d1-4) then autologous HSCT (auto-HSCT) prepared with 
busulfan (4 mg/kg, d-6 to d-3) and melphalan (140 mg/
m2, d-2) or two courses of high-dose AraC (HiDAC). 
Since 2008, patients with intermediate-risk cytogenetic 
and favorable genotype (mutation of NPM1 or CEBPA 
without FLT3-ITD mutation) were no longer allocated to 
allo-HSCT in first CR and mainly received three cycles 
of HiDAC as consolidation. The induction chemotherapy 
for patients older than 60 years (n=38) combined ida (8 
mg/m2, d1-5), AraC (100 mg/m2, d1-7) with (n=17) or 
without (n=21) lomustine (200 mg/m2, d1). Patients 
achieving CR received a consolidation with ida (8 mg/m2, 
d1-3) and AraC (50 mg/m2/12h, d1-5) then maintenance 
therapy with ida at d1 only and the same scheme of AraC. 
Bone marrow AML samples were obtained after informed 
consent in accordance with the Declaration of Helsinki. 
All samples were stored in the HIMIP tumor bank of 
the U1037 Inserm department (n°DC-2008-307-CPTP1 
HIMIP). The study was approved by the institutional 
review board. 
Mutation screening
The mutational status of DNMT3A exon 23 along 
with 3 additional mutations (FLT3 TKD exon 20, IDH1 
and  IDH2 exons 4) were analyzed by high-resolution 
melting (HRM) PCR using the Light  Cycler 480 with 
High Melting Resolution Master Mix 1X (Roche Applied 
Science), with 10 ng genomic DNA, 0.1 μmol/l of each 
primer (see below), and 25 mmol/l MgCl2. HRM PCR 
cycling conditions were initial denaturation at 95°C for 10 
minutes, followed by 50 cycles at 95°C for 10 seconds, 50 
cycles at 63°C for 15 seconds, and 50 cycles at 72°C for 
25 seconds. Melting curve was measured from 72°C to 
95°C, with 25 acquisitions per degree centigrade. Primer 
sequences were as follows: DNMT3A_X23_F1, 5’-CTG 
GCC AGC ACT CAC CCT-3’; DNMT3A_X23_R1, 5’-
TGT TTA ACT TTG TGT CGC TAC CTC A-3’; FLT3_
X20_F2, 5’-TCA CAG AGA CCT GGC CGC-3’; FLT3_
X20_R1, 5’-TGC CCC TGA CAA CAT AGT TGG-3’; 
IDH1_X4_F1, 5’-GGC TTG TGA GTG GAT GGG TAA-
3’; IDH1_X4_R2, 5’-GCA TTT CTC AAT TTC ATA CCT 
TGC TTA-3’; IDH2_X4_R140_F1, 5’-GAA AGA TGG 
CGG CTG CAG T-3’; IDH2_X4_R140_R3, 5’-TGT 
TTT TGC AGA TGA TGG GC-3’; IDH2_X4_R172_F4, 
5’-GAT GTG GAA AAG TCC CAA TGG A-3’; IDH2_
X4_R172_R2, 5’-CAC CCT GGC CTA CCT GGT 
C-3’. Positive cases detected by the HRM analysis were 
sequenced to confirm the mutation. FLT3 exon 13 ITD 
and NPM1 mutation screening were performed using a 
multiplex PCR using Gold Taq DNA polymerase (Applied 
Biosystems) and the following primers: HsNPM1_
X12_F1, 5′-GAA GTG TTG TGG TTC CTT AAC-3’; 
HsNPM1_X12_R1FAM, 5′(FAM)-TGG ACA ACA CAT 
TCT  TGG  CA-3’;  FLT3_NEM_E,  5′-TGG  TGT  TTG 
TCT CCT CTT CAT TGT-3’; and FLT3_NEM_Qned, 
5′(NED)-GTT  GCG  TTC  ATC  ACT  TTT  CCA  A-3’. 
PCR products were analyzed on a sequencer using sizing 
fragment analysis. CEBPA screening was performed 
according to Pabst et al [13].
nod/scId mice xenograft
Adult NOD/SCID mice (6-8 weeks old) were 
sublethally irradiated with 250 cGy of total body irradiation 
24 h before injection of leukemic cells. Leukemia samples 
were thawed at room temperature, washed twice and 
suspended in PBS at a final concentration of 1-2 million 
cells per 200 µL of PBS per mouse for IV injection. Daily 
monitoring of mice for symptoms of disease (ruffled coat, 
hunched back, weakness, or reduced motility) determined 
the time of killing for injected animals with signs of Oncotarget 2011; 2:  850 - 861 853 www.impactjournals.com/oncotarget
distress. If no sign of distress was seen, mice were analyzed 
12 weeks after injection except as otherwise noted. 
For assessment of leukemic engraftment, NOD/SCID 
mice were humanely killed in accordance with IACUC 
protocols. Bone marrow (mixed from tibias and femurs) 
and spleen were dissected in a sterile environment, flushed 
in PBS and made into single cell suspensions for analysis 
by flow cytometry (FACS Calibur, BD Biosciences, San 
Jose, CA USA).
statistical analysis
Comparisons of patient characteristics (covariates) 
were performed using the Mann-Whitney test for 
continuous variables and the Fisher’s exact test for 
categorical variables. Complete remission (CR) was 
defined  following  Cheson  criteria  [14].  In  univariate 
analysis, covariates associated with response to induction 
therapy or outcome were identified using Fisher’s exact 
test then included in a multivariable logistic model. Overall 
survival (OS) and disease-free survival (DFS) rates were 
measured from the date of diagnosis until death and from 
the date of CR until death or relapse, respectively. Patients 
alive were censored at the time of last contact. OS and 
DFS were estimated by the Kaplan-Meier method and 
compared using the log-rank test. All calculations were 
table 1: characteristics of AML patients with intermediate-risk according to DNMT3A exon 23 mutation. 
No DNMT3A   exon 
23 mutation
DNMT3A  exon 
23 mutation
p
Sex- no.
Male 78 17
0.48
Female 77 22
Ag e - y 
Median 53 47
0.051
Range 18-65 20-63
WBC- G/L
Median 14.6 52
<0.0001
Range 0.8-356 1.0-250
Hb - g/dL
Median 9.6 10.4
0.22
Range 4.3-16 4.8-13.2
Platelets- G/L
Median 70 62
0.54
Range 5-964 8-814
FA B A ML subtypes- no.
M0/M1/M2 4/43/45 0/3/6
<0.0001
M4 /M5 26/27 17/11
M6/M7 0/0 0/0
Unclassified 10 1
Normal Karyotype no. (%) 96 (62) 27 (69) 0.46
Mutations- no. /total no. (%)
FLT3-ITD 37/155 (24) 17/39 (44) 0.027
FLT3-TKD 3/62 (5) 1/14 (7) 0.57
NPM1 49/155 (32) 29/39 (74) <0.0001
CEBPA 20/155 (13) 2/39 (5) 0.26
IDH1 16/155 (10) 8/39 (21) 0.10
IDH2 16/155 (10) 5/39 (13) 0.77
KIT exon 17 2/155 (1) 0/39 (0) -
Complete response- no. (%) 126/155 (81) 34/39 (87) 0.48
A llogeneic SCT- no. /total no. (%) 40/155 (26) 16/39 (41) 0.075
A utologous SCT- no. /total no. (%) 28/155 (18) 7/39 (18) 1.00
Relapse- no. /total no. (%) 63/126 (50) 14/34 (41) 0.36
5-year survival (%) 36.5 47.3 -
WBC, white blood cell count; FAB, French American British; SCT, stem-cell transplantation.Oncotarget 2011; 2:  850 - 861 854 www.impactjournals.com/oncotarget
performed using GraphPad Prism software, version 5.0 
(GraphPad Software Inc., La Jolla, CA). Survival-time 
data (DFS and OS) and covariates were analyzed using the 
backward method of Cox proportional hazards regression.
resuLts 
DNMT3A exon 23 mutation is a frequent event in 
adult AML
DNMT3A exon 23 screening was performed on 
available samples coming from 288 AML patients aged 
from 18 to 65-year old and treated in Toulouse between 
2000 and 2009. DNMT3A exon 23 mutations were detected 
in 39 patients (13.5%) occurring almost exclusively at 
the R882 codon (23 R882H; 13 R882C; 2 R882P) and in 
one patient at the W893 codon (W893S). No association 
between DNMT3A exon 23 mutations and age or sex was 
detected.
DNMT3A exon 23 mutations occur exclusively in 
intermediate cytogenetic risk group
Patients were cytogenetically subdivided according 
to the MRC 2010 classification resulting in 46 patients 
with low risk, 194 with intermediate risk and 43 with high 
risk whereas five patients were not classified in absence 
of karyotypes [15]. Patients with a DNMT3A exon 23 
mutation were exclusively identified in the intermediate-
risk group (39/194, 20%) as compared to CBF and high-
risk AML (p<0.001), 27 with a normal karyotype and 12 
with various associated abnormalities, the most frequent 
being an additional copy of the chromosome 8 (3 patients) 
or 13 (2 patients). No DNMT3A exon 23 mutation was 
detected in high or low risk groups. Consequently, we 
Figure 2: Prognostic impact of DNMT3A exon 23 
mutations in 194 AML patients with intermediate-
cytogenetic risk. (A) Disease-free (DFS) and (B) overall 
survival (OS) in patients with or without DNMT3A exon 23 
mutations. DFS and OS were not different between DNMT3A 
exon 23+ and DNMT3A exon 23- patients (p=0.16 and p=0.17, 
respectively).
Figure 2 
A 
B 
table 2: distribution of FLT3-ITD, NPM1 and DNMT3A exon 23 mutations in AML samples sorted from nod/
scId mice
Patient#
Tx
status
Engraftment Gender FAB Karyotype Status DNMT3A FLT3 NPM1 IDH1 IDH2 IDH2 CEBPA KIT
mean% Dx/Rel R132 R140 R172
LAM018 Pre M 5 normal Dx + ITD + WT WT WT WT WT
Post 83 + ITD + WT WT WT WT WT
LAM016 Pre M 5 normal Rel + ITD WT WT WT WT WT WT
Post 81 + ITD WT WT WT WT WT WT
LAM002 Pre M 1 normal Dx + ITD + WT WT WT WT WT
Post 38 + ITD + WT WT WT WT WT
LAM007 Pre F 4 normal Dx + ITD + WT WT WT WT WT
Post 7 + ITD + WT WT WT WT WT
Tx, transplantation; FAB, French American British; Dx, diagnosis; Rel, relapse; WT, wild type; ND, not done.Oncotarget 2011; 2:  850 - 861 855 www.impactjournals.com/oncotarget
focused the analysis exclusively on the 194 patients with 
intermediate-risk. 
DNMT3A exon 23 mutations are associated with 
FAb M4/M5 subtypes and a higher Wbc count
The characteristics of intermediate-risk patients 
according to DNMT3A mutational status are listed in table 
1. A bias toward monocytic differentiation (FAB groups 
M4 and M5) was identified in DNMT3A exon 23+ samples 
(p<0.0001). A strong association was found between 
DNMT3A exon 23+ and a higher white blood cell count 
(p=0.001). Platelet count, hemoglobin concentration and 
marrow blast percentage at diagnosis were similar in 
DNMT3A exon 23+ and – groups.
DNMT3A exon 23 mutations are associated with 
nPM1 and FLt3-Itd mutations
DNMT3A  exon  23  mutations  were  significantly 
associated with FLT3-ITD (17 FLT3-ITD/39  DNMT3A 
exon 23+, 44% vs. 37/155 DNMT3A exon 23-, 24%, 
p=0.027), NPM1 mutations (29 NPM1c/39 DNMT3A exon 
23+, 74% vs. 49/155 DNMT3A exon 23-, 32%, p< 0.001). 
No relationship was identified between DNMT3A exon 23 
mutations and CEBPA mutations, IDH1 R132, IDH2 R140 
and R172 mutations, FLT3 tyrosine kinase domain or KIT 
exon 17 mutations. The significant relationship between 
DNMT3A exon 23 mutations and NPM1 mutations was 
independent of the FLT3-ITD mutation status (p<0.001 
in FLT3-ITD+ or FLT3-ITD- in both groups). In contrast, 
the relationship between DNMT3A exon 23 mutations 
and FLT3-ITD mutations was lost in the NPM1 mutation 
subgroups (p=0.700 in NPM1c - and p=0.043 in NPM1c 
+ patients), suggesting that the relationship between 
DNMT3A and NPM1 mutations was stronger than the 
relationship between DNMT3A and FLT3-ITD mutations.
DNMT3A exon 23 mutations are conserved in 
xenograft mice models
We next analyzed the mutational status of nine primary 
AML samples which showed engraftment capacities in 
xenograft NOD/SCID mice model. The presence of FLT3-
ITD (seven out of nine, data not shown) correlated with 
the ability to engraft in these mice as it has been shown 
earlier [16-18]. Furthermore, we have also observed that 
four of these nine specimens carried the DNMT3A exon 
23+ mutations that were associated with FLT3-ITD and 
NPM1 mutations (Table 2). For these four samples, we 
also analyzed their post-transplantation mutational status 
and found that DNMT3A  exon 23+ mutations were 
conserved in NOD/SCID mice. Overall, these data show 
a stability of the DNMT3A mutations in AML engrafted 
mice and suggest a preferential engraftment of primary 
AML specimens with triple FLT3-ITD/NPM1/DNMT3A 
mutations in immunodeficient mice. 
DNMT3A exon 23 mutations have no prognostic 
impact in adult AML with intermediate-risk 
cytogenetics
Analysis of the therapeutic outcome was performed 
for the 194 intermediate-risk patients. Of these patients, 
160/194 (83%) achieved CR after induction chemotherapy. 
The CR rate did not differ according to DNMT3A exon 23 
mutational status, with 34/39 (87%) and 126/155 (81%) 
CR in the DNMT3A exon 23+ group and DNMT3A exon 
23- group, respectively (p=0.48). CR rate was significantly 
influenced by leukocytosis with a cut-off at WBC>30 G/L 
(95% CI, 0.14-0.68, OR, 0.3, p=0.01) but not by age, 
CEBPA, NPM1 or FLT3-ITD mutations. In the DNMT3A 
exon 23+ group, 16 (41%) and 7 (18%) patients in first CR 
received allo-SCT or auto-SCT as consolidation therapy, 
not significantly different from the DNMT3A exon 23- 
group in which 40 (26%) and 28 (18%) received allo-SCT 
or auto-SCT, respectively. In these complete responders, 
15 events were observed in the DNMT3A exon 23+ group 
and 72 events in the DNMT3A exon 23- group (44% and 
57% of CR patients, respectively). Disease-free survival 
was not significantly different between DNMT3A exon 
23+ (median not reached) and DNMT3A exon 23- patients 
(median DFS, 17.6 months) (95% CI, 0.87-2.33, HR 1.42, 
p=0.16) (figure 2A). There were 17 deaths (44%) in the 
DNMT3A exon 23+ group and 88 (57%) in the DNMT3A 
exon  23-  group.  Overall  survival  was  not  significantly 
different between DNMT3A exon 23+ (median not 
reached) and DNMT3A exon 23- patients (median OS, 
24.7 months) (95% CI, 0.87-2.19, HR 1.38, p=0.17) 
(figure 2B). Among age, WBC count, DNMT3A exon 23 
mutations and FLT3/NPM1 genotypes, the only factor 
that significantly influenced both DFS and OS was the 
FLT3wt/NPM1c genotype (not shown).
AML patients with DNMT3A exon 23 mutations 
may  benefit  from  idarubicin  as  compared  to 
daunorubicin
As we did not find any prognostic impact of DNMT3A 
exon 23+ mutations in contrast to previous studies, we 
tried to find out whether treatments received by DNMT3A 
exons 23+ patients could explain these differences.[9;19-
20] Because patients who were older than 60 received 
idarubicin and lomustin but also because they were much 
less frequently allografted, we focalized our analysis 
on younger patients (60y or less). The characteristics of 
patients according to the type of anthracycline used at 
induction are reported in table 3. There was no difference 
between patients treated by daunorubicin and those Oncotarget 2011; 2:  850 - 861 856 www.impactjournals.com/oncotarget
treated by idarubicin in terms of DFS (median DFS, 22.7 
months for DNR vs 22.8 months for Ida, p=0.90) and OS 
(median OS, 28.5 months for DNR vs 24.4 months for 
Ida, p=0.39). Analysis of covariates associated with both 
DFS and OS are shown in table S1-S2. However, there 
was a significant impact of DNMT3A exon 23 mutations 
in patients treated with idarubicin. DNMT3A exons 23+ 
patients had better DFS (not reached vs 11.6 months, HR 
3.3 , 95% CI, 1.34-8.11, p=0.009) and OS (not reached 
vs 14.3 months, HR 3.1, 95% CI, 1.39-6.71, p=0.005) as 
compared to DNMT3A exons 23- patients when treated 
with idarubicin whereas patients treated with daunorubicin 
had similar outcome regardless the DNMT3A mutational 
status (figure 3). Conversely, the outcome of patients with 
NPM1+/FLT3wt genotype was not impacted by the type 
of anthracycline used in induction (Figure S1). In patients 
who received allo-SCT (n=53), there was a trend for 
improved outcome in DNMT3A exon 23+ patients (DFS 
and OS medians not reached) as compared to DNMT3A 
exon 23- patients (median DFS, 19.1 months, p=0.15; 
median OS, 29.2 months, p=0.1) but the difference did not 
reach statistical significance (figure 4). To better address 
the effects of idarubicin vs. daunorubicin along with other 
variables in DNMT3A  mutated patients, we performed 
univariate and multivariate analysis. As shown in table 4, 
idarubicin had an independent favorable prognostic effect 
on OS (HR 0.27, 95% CI, 0.08-0.97, p=0.046) when 
considering age, karyotype, NPM1/FLT3wt genotype, 
WBC and allo-SCT in DNMT3A mutated patients.
Figure 3 
B 
D 
F  E 
C 
A 
Figure 3: Impact of idarubicin in 156 AML patients ≤ 60y according to DNMT3A exon 23 mutations. DFS (A) and OS 
(B) according to daunorubicin or idarubicin treatment. DFS (C) and OS (D) in patients treated by idarubicin according to DNMT3A exon 
23 mutations. DFS (E) and OS (F) in patients treated by daunorubicin according to DNMT3A exon 23 mutations.Oncotarget 2011; 2:  850 - 861 857 www.impactjournals.com/oncotarget
dIscussIon
In accordance with the first study assessing DNMT3A 
mutations in AML, we confirm here the high prevalence 
of  DNMT3A exon 23 mutations in a series of 288 de 
novo adults AML [9]. We have also observed that these 
mutations were exclusively found within the intermediate-
risk cytogenetic group, associated with M4/M5 FAB 
subtypes and hyperleukocytosis. At the molecular level, 
DNMT3A exon 23 mutations were strongly associated 
with NPM1 mutations and to a lesser extent with FLT3-
ITD  mutations whereas no correlation was found with 
CEBPA, KIT or IDH1/2 mutations.
However, in contrast with previous studies, we 
failed to show any prognostic impact of DNMT3A exon 
23 mutations in AML with intermediate-risk cytogenetic 
[9;19-20]. We acknowledge that our patients had been 
treated over a long period of time (nine years) and this 
could have potentially introduced some bias. Indeed, 
two major changes in the management of AML patients 
had been undertaken in our center during this period of 
time: the introduction of primary prophylaxis of invasive 
fungal infections using azoles (voriconazole from 2003 to 
2008, posaconazole thereafter) [21] and the stratification 
of allo-HSCT indication according to the new molecular 
classification  of  intermediate-risk  AML  using  CEBPA, 
FLT3 and NPM1 mutations. Indeed, patients with wild 
type  FLT3 and CEBPA or NPM1 mutations were no 
longer allocated to allo-HSCT in first CR since the results 
published by Schlenk et al.[5]. However, since these two 
measures were applied in 2003 and 2008 respectively, their 
Figure 4: outcome of allografted patients according 
to DNMT3A exon 23 mutations. DFS (A) and OS (B) in 
DNMT3A exon 23+ patients (n=15) and DNMT3A exon 23- 
patients (n=38) who were allografted in first complete response.
Allogeneic stem-cell transplantation
table 3: characteristics of patients with intermediate-cytogenetic risk according to the type of anthracycline used at 
induction treatment
No DNMT3A  exon 23 mutation DNMT3A exon 23 mutation p
DNR IDA DNR IDA
Sex- no.
Male 39 20 8 6
0.16
Female 48 13 17 5
Age - y 
Median 49 50 47 46
0.81
Range 21-60 18-60 20-60 35-60
WBC- G/L
Median 14.5 17.9 52 41.3
0.0037
Range 0.8-356 1.8-220 1.7-249 1.0-250
Mutations- no. /total no. (%)
FLT3-ITD 20/87 (23) 11/33 (33) 11/25 (44) 4/11 (36) 0.19
NPM1 30/87 (34) 5/33 (15) 19/25 (76) 8/11 (73) <0.0001
CEBPA 12/87 (13) 6/33 (18) 2/25 (8) 0/11 (0) 0.38
IDH1 11/87 (13) 2/33 (6) 6/25 (24) 2/11 (18) 0.24
IDH2 10/87 (11) 2/33 (6) 3/25 (12) 1/11 (9) 0.83
Complete response- no. (%) 73/87 (84) 25/33 (76) 22/25 (88) 10/11 (91) 0.53
Allogeneic SCT- no. /total  no. (%) 27/73 (36) 11/25 (44) 10/22 (45) 5/10 (50) 0.71
Relapse- no. /total no. (%) 32/73 (44) 17/25 (68) 12/22 (55) 1/10 (10) 0.014
5-years survival (%) 40.1 26.9 41.4 72.7 -
DNR, daunorubicin; IDA, idarubicin;  WBC, white blood cell count; SCT, stem cell transplantation.Oncotarget 2011; 2:  850 - 861 858 www.impactjournals.com/oncotarget
impact on outcome, if any, could have been negligible in 
the whole cohort of patients. Furthermore, our induction 
and consolidation regimen have little changed for fifteen 
years, particularly the dosing of anthracyclines, with 
daunorubicin always given at 60 mg/m2/day for three 
days at time of the induction chemotherapy. By contrast, 
the doses of anthracyclines are not fully described in the 
study of Ley et al, in which several induction regimen 
were used, some of them using the infra optimal dose of 
45 mg/m2/d [22-24]. Moreover, some patients received 
hypomethylating agents or lenalidomide which generally 
induce fewer responses than intensive chemotherapy in 
AML patients [25-26]. Also, complete response and early 
death rates were not mentioned and this could be of interest 
as patients with R882 DNMT3A mutations usually have a 
high white blood cell count, a recognized risk factor for 
early death. In our study, DNMT3A exon 23 mutations did 
not impact on both complete response and early death rates. 
Moreover, we found that patients with DNMT3A exon 
23 mutations could specifically benefit from idarubicin 
although the small number of patients in our study 
requires confirmation in larger cohorts. The strong impact 
of DNMT3A mutations on the response to idarubicin as 
compared to daunorubicin is quite unexpected. However, 
it has been recently shown that DNMT3A could play a role 
in anthracyclines-induced apoptosis of colorectal cancer 
cells. Indeed, the expression of DNMT3A is upregulated 
at apoptosis-inducing concentrations of doxorubicin and 
involved in p21 repression thereby blocking senescence 
[27]. Whether this program is induced by idarubicin but 
not daunorubicin in DNMT3A mutated/haploinsufficient 
cells remains to be determined. Alternatively, DNMT3A 
mutations could specifically impact on the expression of 
genes involved in idarubicin metabolism as compared 
to daunorubicin. The broader spectrum of activity of 
idarubicin has been attributed to increased lipophilicity, 
cellular uptake and improved stabilization of a ternary 
drug-topoisomerase II-DNA complex [28]. Thus, 
the discrepancy in therapeutic outcome between our 
series and those previously described could be due to 
differences in treatment intensity or altered metabolism 
of anthracyclines. Several clinical trials have already 
assessed the impact of daunorubicin dose intensification 
or compared idarubicin vs. daunorubicin in large cohorts 
of AML patients. Reassessing results of these controlled 
studies in light of DNMT3A mutational status could 
easily confirm or not our preliminary observations [12;22-
23;29-30]. It remains also to be determined if DNMT3A 
mutations affect in a similar way the metabolism of 
other compounds that intercalates DNA and inhibits 
topoisomerase II such as the new quinolone derivative 
vosaroxin which is currently assessed in AML [31].
In addition, we were also able to demonstrate for 
the first time that DNMT3A mutations are also found in 
table 4: univariate and Multivariate Analysis for dFs and os in DNMT3A exon 23 mutated patients. Analysis of 
covariates associated with DFS and OS. P of the univariate analysis is the p value of the Log rank test. HR is the value of the hazard ratio. 
95% CI is the 95% confident interval of the hazard ratio. Data of AML patients with DNMT3A exon 23 mutations were complete and were 
included in the Cox proportional-hazards regression. NPM1: Nucleophosmin; FLT3-ITD: internal tandem duplication of the FLT3 gene; 
Allo-SCT: Allogeneic stem-cell transplantation; Ida: idarubicin; WBC: white blood cell count.
Univariate analysis Multivariateanalysis
DFS p HR 95% CI p HR 95% CI
Age > 50y 0.94 1.04 0.35-3.09 >0.1
NPM1+/FLT3-ITD- 0.49 0.70 0.25-1.95 >0.1
Normal  karyotype 0.95 1.04 0.33-3.24 >0.1
Allo-SCT 0.13 0.45 0.16-1.26 >0.1
Ida treatment 0.036 0.32 0.11-0.93 0.052 0.21 0.05-1.01
WBC count > 30G/L 0.55 1.43 0.45-4.56 >0.1
OS
Age > 50y 0.76 1.17 0.43-3.14 >0.1
NPM1+/FLT3-ITD- 0.52 0.74 0.29-1.89 >0.1
Normal  karyotype 0.88 1.08 0.39-2.99 >0.1
Allo-SCT 0.06 0.41 0.16-1.04 0.053 0.36 0.12-1.01
Ida treatment 0.046 0.37 0.14-0.98 0.046 0.27 0.08-0.97
WBC count > 30G/L 0.2 2.06 0.69-6.13 >0.1Oncotarget 2011; 2:  850 - 861 859 www.impactjournals.com/oncotarget
leukemic  samples  engrafted  in  immunodeficient  mice. 
Although we could not demonstrate that the DNMT3A 
exon 23 mutation is a surrogate marker of engraftment 
in NOD/SCID mice, it should be noted that all mutated 
samples tested recapitulated the initial disease in 
mice. By comparison, it has been shown that only 
50% of intermediate-risk cytogenetic samples display 
engraftment properties in NOD/SCID mice [32]. This 
suggests that engraftment properties of AML samples 
should be assessed in light of specific molecular lesions. 
It has been shown that engraftment in xenograft NOD/
SCID-IL2Rγc-/- mice model did not correlate with French-
American-British subtype or cytogenetic abnormalities but 
with the presence of FLT3-ITD [17]. More recently, Sarry 
et al. have observed that a high engraftment level occurred 
within human primary AML samples carrying at least two 
mutations (seven out of nine samples had FLT3-ITD and 
NPM1 mutations) and that these mutations were strongly 
conserved in the different leukemic stem cell populations 
sorted as well as still present after the first transplantation 
into NOD/SCID-IL2Rγc-/- mice [18]. In the present study, 
we show that the DNMT3A mutation is also conserved 
through the NOD/SCID xenograft model and is associated 
with higher leukemic engraftment level in cooperation 
with  FLT3-ITD and NPM1 mutations, suggesting that 
this mutation occurs in the early leukemogenic events and 
belongs to the main leukemic clone over the course of the 
disease progression.
In summary, our data confirm that DNMT3A exon 23 
mutations can be easily evaluated in medical practice and 
represent a frequent molecular event in intermediate-risk 
AML associated with NPM1 and FLT3-ITD mutations but 
have no clear impact on disease-free and overall survival. 
However, although this finding needs to be confirmed in 
largest cohort of patients, DNMT3A mutations could be a 
predictive factor for response to idarubicin and, thus could 
have a direct influence in the way AML patients should be 
managed. 
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